K M Abulaban1, H Song2, X Zhang2, P L Kimmel3, J W Kusek3, R G Nelson4, H I Feldman5, R S Vasan6, J Ying7, M Mauer8, G L Nelsestuen8, M Bennett9, H I Brunner9, B H Rovin10. 1. Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, USA Department of Pediatrics, Helen DeVos Childrens Hospital, Michigan State University, Grand Rapids, USA. 2. Department of Internal Medicine, Ohio State University Wexner Medical Center, Columbus, USA. 3. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD. 4. National Institute of Diabetes and Digestive and Kidney Diseases, Phoenix, USA. 5. Department of Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, USA. 6. Preventive Medicine and Cardiology Sections, and Department of Medicine, Boston University School of Medicine, Boston, USA. 7. Department of Environmental Health, University of Cincinnati, Cincinnati, USA. 8. Department of Pediatrics, University of Minnesota, Minneapolis, USA. 9. Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, USA. 10. Department of Internal Medicine, Ohio State University Wexner Medical Center, Columbus, USA Brad.Rovin@osumc.edu.
Abstract
OBJECTIVE: To evaluate candidate biomarkers to predict future renal function decline (RFD) in children and adults with lupus nephritis (LN). METHODS: At the time of enrollment into prospective observational LN cohort studies liver-type fatty acid binding protein (LFABP), albumin, monocyte chemoattractant protein-1 (MCP-1), uromodulin, transferrin, and hepcidin were measured in urine samples of two cohorts of patients with LN, one followed at a pediatric (cohort-1; n = 28) and one at an adult institution (cohort-2; n = 69). The primary outcome was RFD, defined in cohort-1 as a decrease in estimated glomerular filtration rate (eGFR) of ≥20% and in cohort-2 as a sustained increase of ≥25% in serum creatinine concentration (SCr), both from baseline. RESULTS: All patients (n = 97) had normal eGFR or SCr at the time of urine collection at baseline. RFD occurred in 29% (8/28) of patients in cohort-1 during a mean follow-up of 6.1 months, and in 30% (21/69) of those in cohort-2 during a mean follow-up of 60 months. Individually, in cohort-1, levels of MCP-1, transferrin, LFABP, and albumin were higher in the RFD group than those who maintained renal function, with statistical significance for LFABP and albumin. In cohort-2 the RFD group also had higher levels of urine MCP-1 and albumin than others. The combination of LFABP, MCP-1, albumin, and transferrin had good predictive accuracy for RFD in both cohorts (area under the ROC curve = 0.77-0.82). CONCLUSION: The combinatorial urine biomarker LFABP, MCP-1, albumin, and transferrin shows promise as a predictor of renal functional decline in LN, and warrants further investigation.
OBJECTIVE: To evaluate candidate biomarkers to predict future renal function decline (RFD) in children and adults with lupus nephritis (LN). METHODS: At the time of enrollment into prospective observational LN cohort studies liver-type fatty acid binding protein (LFABP), albumin, monocyte chemoattractant protein-1 (MCP-1), uromodulin, transferrin, and hepcidin were measured in urine samples of two cohorts of patients with LN, one followed at a pediatric (cohort-1; n = 28) and one at an adult institution (cohort-2; n = 69). The primary outcome was RFD, defined in cohort-1 as a decrease in estimated glomerular filtration rate (eGFR) of ≥20% and in cohort-2 as a sustained increase of ≥25% in serum creatinine concentration (SCr), both from baseline. RESULTS: All patients (n = 97) had normal eGFR or SCr at the time of urine collection at baseline. RFD occurred in 29% (8/28) of patients in cohort-1 during a mean follow-up of 6.1 months, and in 30% (21/69) of those in cohort-2 during a mean follow-up of 60 months. Individually, in cohort-1, levels of MCP-1, transferrin, LFABP, and albumin were higher in the RFD group than those who maintained renal function, with statistical significance for LFABP and albumin. In cohort-2 the RFD group also had higher levels of urine MCP-1 and albumin than others. The combination of LFABP, MCP-1, albumin, and transferrin had good predictive accuracy for RFD in both cohorts (area under the ROC curve = 0.77-0.82). CONCLUSION: The combinatorial urine biomarker LFABP, MCP-1, albumin, and transferrin shows promise as a predictor of renal functional decline in LN, and warrants further investigation.
Authors: Linda T Hiraki; Bing Lu; Steven R Alexander; Tamara Shaykevich; Graciela S Alarcón; Daniel H Solomon; Wolfgang C Winkelmayer; Karen H Costenbader Journal: Arthritis Rheum Date: 2011-07
Authors: Brad H Rovin; Huijuan Song; Dan J Birmingham; Lee A Hebert; Chack Yung Yu; Haikady N Nagaraja Journal: J Am Soc Nephrol Date: 2004-12-15 Impact factor: 10.121
Authors: Hermine I Brunner; Michael R Bennett; Rina Mina; Michiko Suzuki; Michelle Petri; Adnan N Kiani; Joshua Pendl; David Witte; Jun Ying; Brad H Rovin; Prasad Devarajan Journal: Arthritis Rheum Date: 2012-08
Authors: Claas H Hinze; Michiko Suzuki; Marisa Klein-Gitelman; Murray H Passo; Judyann Olson; Nora G Singer; Kathleen A Haines; Karen Onel; Kathleen O'Neil; Earl D Silverman; Lori Tucker; Jun Ying; Prasad Devarajan; Hermine I Brunner Journal: Arthritis Rheum Date: 2009-09
Authors: Jessica L Turnier; Hermine I Brunner; Michael Bennett; Ashwaq Aleed; Gaurav Gulati; Wendy D Haffey; Sherry Thornton; Michael Wagner; Prasad Devarajan; David Witte; Kenneth D Greis; Bruce Aronow Journal: Rheumatology (Oxford) Date: 2019-02-01 Impact factor: 7.580
Authors: Hermine I Brunner; Michael R Bennett; Gaurav Gulati; Khalid Abulaban; Marisa S Klein-Gitelman; Stacy P Ardoin; Lori B Tucker; Kelly A Rouster-Stevens; David Witte; Jun Ying; Prasad Devarajan Journal: J Rheumatol Date: 2017-06-15 Impact factor: 4.666
Authors: Hermine I Brunner; Gaurav Gulati; Marisa S Klein-Gitelman; Kelly A Rouster-Stevens; Lori Tucker; Stacey P Ardoin; Karen B Onel; Rylie Mainville; Jessica Turnier; Pinar Ozge Avar Aydin; David Witte; Bin Huang; Michael R Bennett; Prasad Devarajan Journal: Pediatr Nephrol Date: 2018-08-29 Impact factor: 3.714
Authors: Abril A Pérez-Arias; R Angélica Méndez-Pérez; Cristino Cruz; María Fernanda Zavala-Miranda; Juanita Romero-Diaz; Sofía E Márquez-Macedo; Roque A Comunidad-Bonilla; C Carolina García-Rueda; Juan M Mejía-Vilet Journal: Clin Rheumatol Date: 2022-09-15 Impact factor: 3.650
Authors: Eileen S Marks; Mathilde L Bonnemaison; Susan K Brusnahan; Wenting Zhang; Wei Fan; Jered C Garrison; Erika I Boesen Journal: Sci Rep Date: 2017-10-09 Impact factor: 4.379